Edition:
United States

Albany Molecular Research Inc (AMRI.O)

AMRI.O on Nasdaq

16.04USD
27 Sep 2016
Change (% chg)

-- (--)
Prev Close
$16.04
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
250,642
52-wk High
$20.65
52-wk Low
$12.45

Latest Key Developments (Source: Significant Developments)

Albany Molecular Research announces restructuring plan of certain operations in U.S.and Europe
Monday, 29 Aug 2016 05:19pm EDT 

Albany Molecular Research Inc : Announced a restructuring plan with respect to certain operations in United States and Europe . Restructuring plan in connection with previously announced acquisition of prime European therapeuticals S.P.A Euticals . Under plan, co expects to incur certain charges related to reduction in force, other transition activities between $5.7 - $7.3 million . Cash charges will consist of $5.5 - $7.1 million of employee and other related costs and will primarily be paid during second half of 2016 .Company expects majority of these charges to be recorded in second half of 2016..  Full Article

Albany Molecular Research reports Q2 loss per share $0.61
Thursday, 4 Aug 2016 07:30am EDT 

Albany Molecular Research Inc : Amri announces second quarter 2016 results . Q2 revenue rose 35 percent to $120.8 million . Q2 loss per share $0.61 . Q2 non-GAAP earnings per share $0.36 . Q2 earnings per share view $0.32 -- Thomson Reuters I/B/E/S . Sees FY 2016 revenue $590 million to $615 million . Sees FY 2016 non-GAAP earnings per share $1.03 to $1.11 .Sees 2016 capital expenditures of approximately $48 million.  Full Article

Albany Molecular Research clarifies 2016 revenue guidance
Tuesday, 10 May 2016 11:34am EDT 

: AMRI clarifies 2016 revenue guidance . Company expects approximately 50% of its 2016 revenue to be realized in first half of year .Continues to expect about 40% of 2016 adjusted eps to be realized in H1,corresponding 60% in second half of year, respectively.  Full Article

AMRI posts Q1 loss of $0.29/share
Tuesday, 10 May 2016 08:00am EDT 

Albany Molecular Research Inc : AMRI announces first quarter 2016 results . Q1 GAAP loss per share $0.29 . Q1 adjusted non-GAAP earnings per share $0.07 . Q1 earnings per share view $0.21 -- Thomson Reuters I/B/E/S . Q1 revenue rose 29 percent to $105.6 million . Sees FY 2016 revenue up 19 percent . Sees FY 2016 revenue $465 million to $490 million . FY adjusted diluted EPS is expected to be between $1.00 and $1.10 . Fy2016 earnings per share view $1.05, revenue view $479.2 million -- Thomson Reuters I/B/E/S . Confirms standalone full year 2016 financial guidance . Q1 contract revenue of $102.8 million, up 37% from 2015 .Sees 2016 capital expenditures of approximately $45 million.  Full Article

Albany Molecular Research Inc gives FY 2016 guidance
Wednesday, 17 Feb 2016 07:31am EST 

Albany Molecular Research Inc:Expects FY 2016 revenue to be between $465 to $490 million.Expects FY 2016 adjusted EPS to be between $1.00 and $1.10 per diluted share.  Full Article

Albany Molecular and NYCNMR form collaborative agreement
Thursday, 14 Jan 2016 08:00am EST 

Albany Molecular:Signed a collaboration agreement with the New York Center for Nanomedicine Research.Collaboration agreement to co-market their nanotechnology services to global pharmaceutical and biotechnology clients.  Full Article

Eagle Pharmaceuticals Inc and AMRI agree to jointly develop parenteral drug products
Monday, 11 Jan 2016 06:50am EST 

Eagle Pharmaceuticals Inc and Albany Molecular Research, Inc:Eagle Pharmaceuticals and AMI announce agreement to jointly develop, manufacture and commercialize parenteral drug products.Says Eagle will be responsible for U.S. commercial distribution of all approved products, once approved by the FDA.AMI will supply products to Eagle pursuant to commercial supply agreement,receive payments based on eagle's sales of products.AMI will develop, initially provide CGMP manufacturing, analytical support for registration of new product candidates.  Full Article

Albany Molecular Research Inc acquires Whitehouse Laboratories
Tuesday, 15 Dec 2015 08:14am EST 

Albany Molecular Research Inc:Acquired all the outstanding equity interests of Whitehouse Laboratories.Total consideration is $54 million in cash, and an additional $2 million in shares of AMRI common stock contingent upon Whitehouse Labs achieving certain 2015 targets.AMRI financed the transaction with cash on hand and borrowings under its $30 million revolving credit facility.Transaction is expected to be accretive in 2016 to AMRI's non-GAAP diluted earnings per share.AMRI intends to provide its 2016 financial guidance in mid-February 2016.  Full Article

Albany Molecular Research Inc and Multispan Ink collaboration agreement
Thursday, 10 Dec 2015 08:00am EST 

Albany Molecular Research Inc:Says has signed collaboration agreement with biotechnology company Multispan Inc. to co-market their G protein-coupled receptor (GPCR) drug discovery services to global pharmaceutical and biotechnology clients.Says as part of three-year agreement, AMRI gains access to Multispan's uniquely differentiated GPCR cell lines, assay capabilities and expertise.  Full Article

Albany Molecular Research Inc reaffirms FY 2015 guidance
Thursday, 5 Nov 2015 07:00am EST 

Albany Molecular Research Inc:Reiterates FY 2015 total revenue of $400 to $416 million; adjusted EPS guidance maintained at between $0.90 and $0.95 per diluted share.Expects FY 2015 Adjusted EBITDA between $75 and $78 million.FY 2015 revenue of $408 mln EBITDA of $73.48 mln and EPS of $0.92 - Thomson Reuters I/B/E/S.  Full Article

BRIEF-Albany Molecular files for secondary offering of 7 million shares of its common stock

* Albany Molecular files for secondary offering of 7 million shares of its common stock - SEC filing Source text for Eikon: Further company coverage: